A Cross-Sectional Study Evaluating The Prevalence Of Non-Alcoholic Fatty Liver Disease (NAFLD) In Patients With Inflammatory Bowel Disease (IBD) Receiving Anti-Tumor Necrosis Factor (anti-TNF) Therapy And The Clinical Variables Associated With Both Disorders.
Phase of Trial: Phase IV
Latest Information Update: 26 May 2017
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 26 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017.